AVTR vs. ILMN, WAT, RVTY, BIO.B, BIO, LH, HOLX, BMRN, TEVA, and BGNE
Should you be buying Avantor stock or one of its competitors? The main competitors of Avantor include Illumina (ILMN), Waters (WAT), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Laboratory Co. of America (LH), Hologic (HOLX), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), and BeiGene (BGNE). These companies are all part of the "medical" sector.
Illumina (NASDAQ:ILMN) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Illumina received 911 more outperform votes than Avantor when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 63.64% of users gave Avantor an outperform vote.
In the previous week, Illumina had 23 more articles in the media than Avantor. MarketBeat recorded 26 mentions for Illumina and 3 mentions for Avantor. Illumina's average media sentiment score of 1.51 beat Avantor's score of 0.24 indicating that Avantor is being referred to more favorably in the news media.
Avantor has higher revenue and earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
89.4% of Illumina shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.2% of Illumina shares are held by company insiders. Comparatively, 1.5% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Illumina presently has a consensus price target of $164.65, suggesting a potential upside of 48.96%. Avantor has a consensus price target of $26.71, suggesting a potential upside of 7.76%. Given Avantor's higher possible upside, analysts plainly believe Illumina is more favorable than Avantor.
Avantor has a net margin of 3.79% compared to Avantor's net margin of -28.71%. Illumina's return on equity of 13.01% beat Avantor's return on equity.
Illumina has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Avantor beats Illumina on 13 of the 18 factors compared between the two stocks.
Get Avantor News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
